Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health | FMCG | Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Mark on +44 1494 818 049 or markd@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Mark Denton
Managing Director
markd@zenopa.com
+44 1494 818 049

Testimonials
I have been working through a contract with Zenopa since March 2012. I actually find this approach more beneficial to me as I have someone independent from the company who I can talk to about any issu...
Jennifer, 2012

Bristol-Myers Squibb declares quarterly dividend

22 December 2008 00:00 in Pharmaceutical Company Financials


Bristol-Myers Squibb has announced its quarterly dividend.

The company's board of directors announced the amount to be $0.31 (0.21 pounds) per share on the $.10 par value common stock of the organisation.

Set to be payable to stockholders on February 2nd next year, the transaction follows the close of business on January 2nd 2009.

The board also declared a quarterly dividend of $0.50 per share on the $2 convertible preferred stock of the company.

Payable on March 2nd to stockholders of record, it follows the close of business on February 6th.

The board said it expected dividend for the full year of 2009 of $1.24 per share on the $0.10 par value common stock, subject to the quarterly review.

Last week, Bristol-Myers Squibb announced new data from phase III breast cancer studies.

The research of the drug Ixempra plus capecitabine sought its efficacy and safety, in comparison to capecitabine on its own.

It involved 2,000 patients and those on the amalgamation therapy had an overall response rate of 31 per cent, in contrast to 15 per cent.

Bristol-Myers Squibb added the progression free survival of the combination group was a median of 4.2 months, compared to 1.7 months for the singular drug-treated group.

Other news stories from 22/12/2008

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency



   
© Copyright 2013 Zenopa Ltd